Most Read Articles
Pearl Toh, 2 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
Rachel Soon, 05 Dec 2018

At the recent Malaysian Community Pharmacy Business Forum (MyCPBF), a discussion forum was held on the subject of “Transcending Primary Healthcare Services: The Future of Specialized Pharmacy Services and Pharmacy Specialization”.

Dr Renly Lim, 01 Aug 2018
Palliative care uses an integrated, multidisciplinary approach to reduce suffering and to improve the quality of life of patients battling with life-threatening illnesses.
Audrey Abella, 28 Nov 2018
Use of the oral anticoagulant rivaroxaban at a low dose may reduce the risk of thromboembolic events* in patients with heart failure (HF), according to a post hoc analysis of the COMMANDER HF** trial.

Direct-acting antivirals prevent infection in non–HCV-infected kidney transplant recipients

09 Mar 2018

Apart from being tolerable and feasible, pre- and post-transplantation hepatitis C virus (HCV) treatments prevent HCV infection in non–HCV-infected recipients (ie, HCV D+/R transplantation) of kidneys, a recent open-label nonrandomized trial in a single centre has shown.

In total, there were 10 HCV D+/R transplant recipients included in this study. Treatment-related adverse events did not occur in any of the participants, and HCV RNA was not detected at 12 weeks following HCV treatment.

“If confirmed in larger studies, this strategy should markedly expand organ options and reduce mortality for kidney transplant candidates without HCV infection,” the authors said.

In this trial, 10 HCV D+/R kidney transplant candidates (aged >50 years) with no available living donors were assessed to determine the safety and efficacy of using direct-acting antivirals (DAAs) as prophylaxis before and after kidney transplantation from HCV-infected donors to non–HCV-infected recipients.

Transplanted kidneys were from deceased donors (aged 13–50 years) with positive HCV RNA and HCV antibody test results. All recipients were administered grazoprevir (GZR) 100 mg and elbasvir (EBR) 50 mg immediately prior to transplantation.

Patients receiving kidneys from donors with genotype 1 infection continued taking GZR-EBR for 12 weeks post-transplantation, and recipients of organs from donors with genotype 2 or 3 infection received sofosbuvir 400 mg added to GZR-EBR for 12 weeks of triple therapy.

The incidence of GZR–EBR treatment-related adverse events was the primary safety outcome, while the primary efficacy outcome was the proportion of recipients with an HCV RNA level below the lower limit of quantification 12 weeks after prophylaxis.

“Given the high mortality rate for patients with end-stage kidney disease receiving dialysis and the efficacy and safety of HCV treatments, discarded kidneys from HCV-infected donors may be a neglected public health resource,” according to the authors, adding that the trial was limited by its nonrandomized design and the small number of patients.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 2 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
Rachel Soon, 05 Dec 2018

At the recent Malaysian Community Pharmacy Business Forum (MyCPBF), a discussion forum was held on the subject of “Transcending Primary Healthcare Services: The Future of Specialized Pharmacy Services and Pharmacy Specialization”.

Dr Renly Lim, 01 Aug 2018
Palliative care uses an integrated, multidisciplinary approach to reduce suffering and to improve the quality of life of patients battling with life-threatening illnesses.
Audrey Abella, 28 Nov 2018
Use of the oral anticoagulant rivaroxaban at a low dose may reduce the risk of thromboembolic events* in patients with heart failure (HF), according to a post hoc analysis of the COMMANDER HF** trial.